Last updated on August 2017

Palbociclib In Progressive Brain Metastases


Brief description of study

This research study is studying palbociclib as a possible treatment for recurrent brain metastases. - Pfizer, a pharmaceutical company, is supporting this research study by providing the study drug as well as funding for research activities

Detailed Study Description

- This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. - This is a study designed to evaluate the efficacy and safety of palbociclib in recurrent brain metastases. Palbociclib is being studied for use in the treatment of a broad range of cancers. This type of drug inhibits cell growth in the cells called cyclin-dependent kinases which promote tumor cell proliferation. - The FDA (the U.S. Food and Drug Administration) has not approved palbociclib for participants specific disease but it has been approved for other uses

Clinical Study Identifier: NCT02896335

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Priscilla Brastianos, MD

Massachusetts General Hospital
Boston, MA United States
  Connect »

Eudocia Lee, MD

Dana Farber Cancer Institute
Boston, MA United States
  Connect »